A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy

Abroad (travel likely)RecruitingPHASE2

Conditions

IgA Nephropathy (IgAN)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Peking University First Hospital, Beijing, China
Peking University First Hospital, Beijing, China
Contact: Study coordinator (Zhang hong Zhang) · hongzh@bjmu.edu.cn · 13811123738

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

IgA Nephropathy (IgAN)

Abroad (travel likely)RecruitingPHASE3

Huangshan City, China · Wuhu, China

Atacicept in Multiple Glomerular Diseases

pMN · IgAN · Nephrotic Syndrome

Abroad (travel likely)RecruitingPHASE2

Brisbane, United States

A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy

IgA Nephropathy (IgAN)

Abroad (travel likely)RecruitingPHASE2

Beijing, China

Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)

IgA Nephropathy (IgAN)

Abroad (travel likely)RecruitingPHASE2

Jacksonville, United States · Rochester, United States